Pfizer CEO Albert Borla has said that an oral drug may be ready next year to treat coronavirus. He said that the company is working on two antiviral drugs. Albert said in an interview with CNBC that “We are working on two antiviral drugs, one is tonable and the other is oral. Oral medicine has many benefits. One of the advantages is that you can use it as an injectable drug. It’s hospital. No need to go and you can take it home. “
Approval expected by the end of the year
Albert said “If all goes well and we keep the same pace and if approved on time I hope to have it available by the end of the year. There is currently only one for use in the treatment of coronaviruses.” The antiviral drug Remadecivir has been approved by Gilead Sciences. The US Food and Druggista (FDA) approved the drug in October as a full-time approval, while in May last year it was approved for emergency use.
Multiple variants of Corona claim to be effective
Borla also stated that the drug may be more effective against multiple variants of the virus than current alternatives. He said that “we believe that this drug will be more effective against many variants. So it is good news for everyone and we are progressing in the study”.